Novartis: ranked 1st in the Access to Medicine Index

(CercleFinance.com) - Novartis announces that its first-place ranking in the Access to Medicine Index 2024 (ATMI) underscores its leadership role in improving access to medicines worldwide.


The biennial report assesses 20 leading pharmaceutical companies on their efforts to make medicines accessible in 113 low- and middle-income countries.

The report highlights the Novartis portfolio and pipeline for priority diseases such as malaria and dengue fever, as well as its access strategies for advanced candidates.

' This ranking reflects our fundamental commitment to making innovative medicines accessible, no matter where patients live', says Vas Narasimhan, Novartis CEO.

The company says it will have reached 284 million patients by 2023, including 33.2 million through its access initiatives.

Copyright (c) 2024 CercleFinance.com. All rights reserved.